Lung Transplant Group, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China.
J Occup Environ Med. 2011 Aug;53(8):845-9. doi: 10.1097/JOM.0b013e3182260e50.
To evaluate whether lung transplantation conferred acceptable survival compared with conventional treatment for end-stage silicosis.
We retrospectively analyzed data for five consecutive patients with silicosis between September 2002 and December 2010, four underwent single lung transplantation and one bilateral lung transplantation.
There was no perioperative mortality. Extracorporeal membrane oxygenation was required in four patients, three underwent single lung transplantation and one received bilateral lung transplantation, three of them were successfully weaned. One developed primary graft dysfunction 2 days after transplant and died of multiple organ failure on postoperative day 8. The remaining four patients were discharged from hospital. During follow-up, one recipient died of severe infection 7 months after transplant. All remaining patients returned to work and had a good quality of life after 5, 3 and 2 years, respectively.
Lung transplantation offers effective therapy for patients with end-stage silicosis.
评估肺移植治疗末期矽肺与传统治疗相比是否具有可接受的生存率。
我们回顾性分析了 2002 年 9 月至 2010 年 12 月期间连续 5 例矽肺患者的数据，其中 4 例接受了单肺移植，1 例接受了双肺移植。
无围手术期死亡。4 例患者需要体外膜氧合，其中 3 例接受了单肺移植，1 例接受了双肺移植，3 例成功脱机。1 例在移植后第 2 天发生原发性移植物功能障碍，并在术后第 8 天死于多器官衰竭。其余 4 例患者出院。在随访期间，1 例患者在移植后 7 个月死于严重感染。所有其余患者分别在 5、3 和 2 年后恢复工作，生活质量良好。
肺移植为末期矽肺患者提供了有效的治疗方法。
